<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124368</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-201</org_study_id>
    <secondary_id>2016-003525-42</secondary_id>
    <nct_id>NCT03124368</nct_id>
  </id_info>
  <brief_title>A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN</brief_title>
  <official_title>A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether ACH-0144471 can increase blood C3
      levels in participants with low C3 levels due to either C3G or IC-MPGN.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Actual">January 8, 2019</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Blood C3 levels at Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs), Grade 3 or Higher Adverse Events (AEs), and AEs Leading to Discontinuation</measure>
    <time_frame>up to Day 49</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in Days) to Achieving Peak C3 Levels From the First Day of Dosing</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve (AUC)</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics: Time to maximum concentration (Tmax)</measure>
    <time_frame>Days 1 &amp; 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Biomarkers of Alternative Pathway (AP) activity (AP Wieslab, factor D, and Bb)</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between ACH-0144471 exposure and changes in C3 levels and other biomarkers of alternative pathway activity (AP Wieslab, factor D, and Bb)</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>C3 Glomerulonephritis</condition>
  <condition>Dense Deposit Disease</condition>
  <condition>Membranoproliferative Glomerulonephritis, Type II</condition>
  <condition>C3 Glomerulopathy</condition>
  <condition>Immune Complex Mediated Membranoproliferative Glomerulonephritis</condition>
  <arm_group>
    <arm_group_label>Sentinel Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive ACH-0144471 during the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive ACH-0144471 during the treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471</intervention_name>
    <description>Participants will receive study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period)</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Sentinel Group 1</arm_group_label>
    <other_name>ACH-4471</other_name>
    <other_name>ACH4471</other_name>
    <other_name>4471</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a clinical diagnosis of C3G (C3 glomerulonephritis [C3GN] or dense deposit
             disease [DDD], the 2 types of C3G) or idiopathic immune-complex membranoproliferative
             glomerulonephritis (IC-MPGN) by renal biopsy for at least 3 months prior to dosing,
             with the pathologic diagnosis verified by review of the renal biopsy by the study
             central pathologist

          -  C3 must be &lt;50% of the lower limit of normal

          -  C4 must be &gt;90% of the lower limit of normal

          -  Must be willing to comply with study-specific vaccination requirements for Haemophilus
             influenzae, Streptococcus pneumoniae, and Neisseria meningitidis strains A, C, W, and
             Y

          -  Negative pregnancy test for females prior to dosing and throughout the study

        Exclusion Criteria:

          -  History of a major organ transplant (e.g., heart, lung, kidney, liver) or
             hematopoietic stem cell/marrow transplant. Individuals receiving renal replacement
             therapy are also excluded

          -  Evidence of monoclonal gammopathy of unclear significance (MGUS), infections,
             malignancy, autoimmune diseases, or other conditions to which C3 glomerulopathy or
             IC-MPGN may be secondary

          -  Estimated glomerular filtration rate (eGFR; using MDRD equation) &lt;45 mL/min/1.73 m2 at
             the time of screening or at any time over the preceding four-weeks

          -  Receipt of eculizumab at any dose or interval within the past 75 days prior to dosing

          -  Use of tacrolimus or cyclosporine within 2 weeks of the first dose of ACH-0144471

          -  History of febrile illness, a body temperature &gt;38Â°C, or other evidence of a
             clinically significant active infection, within 14 days prior to study drug
             administration

          -  History of meningococcal infection, or a first-degree relative or household contact
             with a history of meningococcal infection

          -  Females who are pregnant, nursing, or planning to become pregnant during the study or
             within 90 days of study drug administration or patients with a female partner who is
             pregnant, nursing, or planning to become pregnant during the study or within 90 days
             of study drug administration

        NOTE: Additional inclusion/exclusion criteria may apply, per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amalia Children's Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <disposition_first_submitted>November 5, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 5, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 7, 2019</disposition_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>factor D</keyword>
  <keyword>fD</keyword>
  <keyword>alternative pathway</keyword>
  <keyword>complement mediated disease</keyword>
  <keyword>idiopathic MPGN</keyword>
  <keyword>MPGN Type I</keyword>
  <keyword>MPGN Type II</keyword>
  <keyword>MPGN Type III</keyword>
  <keyword>Primary MPGN</keyword>
  <keyword>MCGN</keyword>
  <keyword>Mesangiocapillary Glomerulonephritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

